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hyperlipidemia was made concurrently with the index event in 28.5% and 16.8% of 
patients, respectively. CONCLUSIONS: High SrUA appears associated with increased 
risk of hypertension; very low SrUA may also be associated with hypertension risk. 
Approximately 20% of patients were diagnosed with hypertension or hyperlipidemia 
concurrently with the gout diagnosis, suggesting that gout was the event that initiated 
recognition of these comorbidities, and that, at least in this population, healthcare 
encounters may be symptomatically driven, with lower utilization for preventive care. 
Further evaluation of the relationship between SrUA and onset of hypertension and 
hyperlipidemia is warranted.
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OBJECTIVES: Axial Spondyloarthritis (axSpA) is an inflammatory arthritic disease 
characterized by involvement of the spine, sacroiliac joints or both. Subtypes of 
axSpA include non-radiographic axial spondyloarthritis (nr-axSpA) without radio-
graphic sacroilitis confirmation, and ankylosing spondylitis (AS) with radiographic 
sacroilitis confirmation. These diseases are recognized within a spectrum of dis-
ease. Evidence suggests further stratification of nr-axSpA (e.g., MRI +/- or CRP +/-) 
may clarify the continuum of axSpA and improve clinical practice. Study objectives 
include illustrating burden of illness (BOI) similarities between the classic and fur-
ther stratified axSpA categories to suggest an improved diagnosis paradigm, and 
comparing BOI findings between nr-axSpA and AS subgroups to inform clinical 
practice. METHODS: English-language literature was searched systematically in 
Ovid SP, MEDLINE and EMBASE (2009–2014) for studies that described BOI charac-
teristics of nr-axSpA and AS including prevalence, disease activity, functioning, 
HRQL, productivity and medication utilization. PICO statement (population, inter-
vention, comparator and outcome) search terms were used. Supplementary records 
were obtained by searching American College of Rheumatology 2012 & 2013 and 
European League Against Rheumatism 2013 & 2014 scientific meeting abstracts. 
Additionally, electronic trial registries (e.g., clinicaltrials.gov), the USFDA website 
and article references were searched. RESULTS: 375 papers were retrieved and 
de-duplicated. Of the remaining 315 papers, 25 were selected per defined criteria. 
BOI in nr-axSpA and AS groups differed by gender, but were similar for all other 
categories (e.g., HRQL, functioning, productivity, etc.) indicating the two conditions 
pose a similar burden on patients. Nr-axSpA may be heterogeneous in presenta-
tion and follow a self-limiting or slowly-progressive disease course often seen in 
females (who may have lower inflammation activity). Although data for stratified 
groups (MRI+/-) within nr-axSpA was reported in one study, the evidence suggests 
similar BOI patterns. CONCLUSIONS: Future research should incorporate stratified 
nr-axSpA patient data for diagnostic comparisons and to inform clinical practice.
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OBJECTIVES: Male osteoporosis is a common but neglected public health problem. 
This may be a result of limited data evaluating the efficacy of bisphosphonates 
for fracture prevention in males. This systematic review and meta-analysis study 
assessed the efficacy of bisphosphonates versus placebo in preventing fractures 
among males. METHODS: We searched PubMed/MEDLINE, Embase, Cochrane 
Clinical Trials Library, Clinicaltrials.gov, and Scopus. All randomized placebo-con-
trolled trials of alendronate, ibandronate, risedronate, or zoledronic acid with report-
ing fracture outcomes were assessed. The trials had to include males, be at least 
one year’s duration, and utilize the United States. Food and Drug Administration 
approved bisphosphonate dosing. The outcomes of interest included clinical ver-
tebral, morphometric vertebral, non-vertebral, hip, and any fracture. Fixed-effect 
models were used in both primary and subgroup meta-analyses. Publication bias 
was examined using funnel plots and Egger’s test. Meta-regressions were conducted 
to examine age, body mass index, bone mineral density T-scores, and proportion 
of male participants on the treatment effect. A sensitivity analysis using random 
effects assumption was also conducted. RESULTS: 43 studies were included in this 
meta-analysis; 19 of them reported separate fracture for males. Bisphosphonates 
had significant effects on reducing any fractures (Total population: Relative Risk 
(RR)= 0.63, 95% Confidence Interval (CI)= 0.50-0.79; Male population: RR= 0.58, 
95%CI= 0.36-0.85) and morphometric vertebral fractures (Total population: RR= 0.45, 
95%CI= 0.32-0.63; Male population: RR= 0.40, 95%CI= 0.22-0.73). There was very little 
evidence of heterogeneity (Total population: I2= 0.0%; Male population: I2= 11.9%-
15.3%). A visual inspection of the funnel plots and the Egger’s tests (Total popu-
lation: p= 0.119; Male population: p= 0.690) indicated no evidence of publication 
bias. Moreover, meta-regression showed effect size was unrelated to male pro-
portion. There was no significant superior treatment effect on other fracture out-
comes. CONCLUSIONS: Bisphosphonates significantly reduced vertebral fracture, 
and the effect was consistent regardless of male proportions. This supports use of 
bisphosphonates in males at risk for fracture.
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OBJECTIVES: To compare the disease status and outcomes of patients with RA 
receiving adalimumab and etanercept monotherapy in the US. METHODS: A 
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OBJECTIVES: To quantify the frequency of and excess cost associated with for-
eign objects (e.g., surgical instruments and sponges) left in the body during total 
joint arthroplasty (TJA). METHODS: Data from the 2009-2012 National/Nationwide 
Inpatient Samples (NIS) were analyzed using descriptive (i.e., frequencies and 
means) and bivariate statistical methods (i.e., t-test, chi-square, and their non-
parametric equivalents). Patients that underwent TJA were identified through 
International Classification of Diseases, 9th Revision (ICD-9) procedure codes 81.51 
(hip TJA) and 81.54 (knee TJA). Patients with retained foreign objects were identi-
fied using ICD-9 external causes of injury code E871.0. NIS sample weights were 
used to generate national incidence estimates. Costs were estimated using the 
NIS’ charge-to-cost ratio for each hospital. All costs are reported in 2014 dollars 
using Consumer Price Index adjustment factors. We were only able to quantify the 
frequency and excess cost associated with foreign objects identified and reported 
during the peri-operative period (i.e., initial hospitalization). RESULTS: Included in 
the NIS were 761,225 patients that underwent TJA during the study period. Of these 
patients, only 44 (0.01%) had a retained foreign object (20 hip TJA and 24 knee TJA); 
however, TJA patients accounted for 4.5% of all surgical patients with a hospital-
reported retained object. These TJA patients underwent one additional procedure, 
on average, than those without a retained object (p< 0.0001). We estimate the total 
annual frequency of these events at 55 TJA patients. The estimated average excess 
cost of these avoidable adverse events is $4,950 (p= 0.0068). CONCLUSIONS: Despite 
considerable effort aimed at reducing the frequency in which foreign objects are 
inadvertently left in the body during surgery, these avoidable events continue to 
occur in TJA. While retained objects are rare events in TJA, these adverse events 
lead to excess cost and procedural burden for patients. Quality improvement efforts 
should continue unitl these events are eliminated.
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OBJECTIVES: In US, falls are the leading cause of injury deaths among older adults and 
rate of fall-related deaths has risen significantly over the past decade. Medications 
with sedative or hypnotic properties are known to increase fall risk, but are frequently 
prescribed to older adults. Thus, this study aims to provide more accurate estimate 
risk of falls in older adults taking sedative-hypnotic drugs by accounting for inad-
equately addressed variables (e.g., off-label sedative-hypnotic use, and potential 
confounders not found in claims data). METHODS: Study population were commu-
nity-dwelling older adults, age > 65, with Medicare Part A, B and D coverage. In addition 
to socio-demographic, health, behavioral, and environmental factors, beneficiaries’ 
past year fall and other fall-related information were collected from 2007 and 2009 fall 
supplements in Medicare Beneficiary Survey. Medication and comorbidity informa-
tion were collected from Medicare claims data. Sedative-hypnotic drugs consisted of 
antidepressants with sedating properties, benzodiazepines, and non-benzodiazepine 
hypnotics. Total drug day supply was calculated for each beneficiary to indirectly 
observe cumulative dose effect. Logistic regression was conducted to assess the asso-
ciation between sedative-hypnotic use and falls. RESULTS: A total 2,823 beneficiaries 
were included in the study. Proportion of those who reported past year fall were 33% 
for users and 21% for non-users (p< 0.01). When adjusted for socio-demographic and 
other covariates, sedative-hypnotic users were 1.5 times more likely to report a fall 
past year (OR 1.5, 1.2-2.0[PY1]); and 1.9 times for users with > 1 sedative-hypnotic 
drug class (1.9, 1.2-3.0). Only the users with < 90 day supply of sedative-hypnotics 
showed no increase in odds for past year fall. CONCLUSIONS: Sedative-hypnotic 
use was associated with increased risk of falls among older adults. Short-term use 
(< 90 day supply) of sedative-hypnotic drugs may provide a safer treatment strategy 
for this population. [PY1]95% confidence interval is provided for each odds ratio (OR)
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OBJECTIVES: To use electronic health records (EHR) data to evaluate relationships 
of serum uric acid (SrUA) levels with hypertension and hyperlipidemia in patients 
with gout. METHODS: This retrospective study used de-identified EHR data from 
the Humedica database between 2010 and 2013. Patients were adults (≥ 18 years) 
with ≥ 2 ICD-9-CM diagnosis codes for gout ≥ 30 days apart (first diagnosis = index 
event), with ≥ 1 SrUA assessments, and ≥ 6 months pre- and ≥ 12 months post-index 
activity. Hypertension and hyperlipidemia were based on ICD-9 codes; patients with 
a hypertension or hyperlipidemia diagnosis during the 6-month pre-index period 
were excluded. Patients were stratified by SrUA quartiles: 0.01-4.0mg/dL (n= 2730), 
4.1-6.0mg/dL (n= 4349), 6.1-8.0mg/dL (n= 6136), and ≥ 8.1mg/dL (n= 5744). RESULTS: 
Patients were male (76.8%), white (81.1%) with mean±SD age of 60.5±14.1 years and 
mean±SD Charlson Comorbidity Index of 0.63±1.20. There were no significant differ-
ences across SrUA quartiles for proportions of patients diagnosed with hyperlipidemia 
12-months post-index, which ranged from 37.6% (4.1-6.0mg/dL) to 38.2% (0.01-4.0mg/
dL). In contrast, the ≥ 8.1mg/dL quartile had a significantly higher incidence of hyper-
tension, 60.3% (P< 0.001 versus all other quartiles), and the 0.01-4.0mg/dL quartile was 
significantly greater relative to the 4.1-6.0mg/dL quartile (56.1% vs 53.6%; P< 0.05) 
but similar to the 6.1-8.0mg/dL quartile (54.5%). The diagnosis of hypertension or 
